The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to recent news item captioned Trump Tariff News Live: GSK and AstraZeneca among top companies told to 'cut US prices or else'. The response from the Company is attached.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE and BSE asked GlaxoSmithKline Pharmaceuticals Limited for clarification on a Moneycontrol news article titled 'Trump Tariff News Live: GSK and AstraZeneca among top companies told to cut US prices or else'. The company has clarified that the news article does not pertain to the Indian listed entity (GlaxoSmithKline Pharmaceuticals Limited). Instead, it relates to GSK plc, the ultimate parent company based in the United Kingdom. The company stated it has no further information on the events described and cannot comment on any material impact on itself. It also confirmed it is not aware of any undisclosed information or pending announcement that could affect its share price, and has nothing to disclose under SEBI's Regulation 30.
The news article concerns the UK parent GSK plc, not the Indian listed subsidiary, so it is unlikely to have any direct material impact on GlaxoSmithKline Pharmaceuticals Limited's share price or operations. Shareholders should note this is a routine clarification to avoid confusion, not new business information.